Novel dietary herbal preparations with inhibitory activities against multiple SARS-CoV-2 targets: A multidisciplinary investigation into antiviral activities
{"title":"Novel dietary herbal preparations with inhibitory activities against multiple SARS-CoV-2 targets: A multidisciplinary investigation into antiviral activities","authors":"Olujide Oludayo Olubiyi , Francis Alfred Attah , Birgit Strodel , Raphael Josef Eberle , Monika Aparecida Coronado , Oluwadotun Akinseinde , Augustine Anayochukwu Onyeaghala , Ikemefuna Chijioke Uzochukwu , Olayinka Adejoke Kotila , Hannah Dada-Adegbola , Awodayo Oluwatoyin Adepiti , Anthony Adebolu Elujoba , Chinedum Peace Babalola","doi":"10.1016/j.focha.2025.100969","DOIUrl":null,"url":null,"abstract":"<div><div>The outbreak of the COVID-19 pandemic has resulted in not <7.1million deaths globally as of December 2024. Many new variants of concern have continued to emerge since the initial outbreak of the original SARS-CoV-2 virus traceable to the Wuhan strain (Wuhan-Hu-1). In this work, the therapeutic potentials of four new polyherbal dietary preparations – VIVE (five plants), FORTE1(fortified VIVE), COMBI-5 (five spices) and MOK (Moringa seed) as well as four individual ethnomedicinal plants were investigated. Computational screening revealed chemical structures capable of establishing moderate to strong interaction with SARS-CoV-2′s main protease enzyme, while in vitro screening against the viral protease clearly established inhibitory potencies. The individual plant extracts making up VIVE and FORTE1 showed mild (494.9 ± 19.6 µg/ml) to moderate (21.5 ± 1.1 µg/ml) inhibitory activity against the viral enzyme <em>in vitro</em>; highest activity was obtained in the polyherbal VIVE preparation (17.3 ± 1.4 µg/ml). The MOK exerted total inhibition – 100 % (IC<sub>50</sub> -3.6 ± 0.9) of the viral enzyme while COMBI-5 produced an inhibition of 95 %(IC<sub>50</sub> - 0.9 ± 0.1). These results revealed the potential of specialized metabolites within these widely consumed dietary herbal products for the management of COVID-19 and related viral threats.</div></div>","PeriodicalId":73040,"journal":{"name":"Food chemistry advances","volume":"7 ","pages":"Article 100969"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Food chemistry advances","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772753X25000851","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The outbreak of the COVID-19 pandemic has resulted in not <7.1million deaths globally as of December 2024. Many new variants of concern have continued to emerge since the initial outbreak of the original SARS-CoV-2 virus traceable to the Wuhan strain (Wuhan-Hu-1). In this work, the therapeutic potentials of four new polyherbal dietary preparations – VIVE (five plants), FORTE1(fortified VIVE), COMBI-5 (five spices) and MOK (Moringa seed) as well as four individual ethnomedicinal plants were investigated. Computational screening revealed chemical structures capable of establishing moderate to strong interaction with SARS-CoV-2′s main protease enzyme, while in vitro screening against the viral protease clearly established inhibitory potencies. The individual plant extracts making up VIVE and FORTE1 showed mild (494.9 ± 19.6 µg/ml) to moderate (21.5 ± 1.1 µg/ml) inhibitory activity against the viral enzyme in vitro; highest activity was obtained in the polyherbal VIVE preparation (17.3 ± 1.4 µg/ml). The MOK exerted total inhibition – 100 % (IC50 -3.6 ± 0.9) of the viral enzyme while COMBI-5 produced an inhibition of 95 %(IC50 - 0.9 ± 0.1). These results revealed the potential of specialized metabolites within these widely consumed dietary herbal products for the management of COVID-19 and related viral threats.